FINWIRES · TerminalLIVE
FINWIRES

Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says

By

Inspire Medical Systems (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.

The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.

The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.

The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.

BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.

Shares of Inspire Medical were down nearly 4% in Friday trading.

Price: $43.07, Change: $-1.67, Percent Change: -3.73%

Related Articles

Wire

Update: BofA Securities Cuts Price Target on Walmart to $144 From $150, Maintains Buy Rating

(Updated with BofA's commentary).BofA Securities lowered its price target on Walmart (WMT) to $144 from $150, while defending the stock on the pullback following its fiscal Q1 results.Walmart's share gains are expected to accelerate with a price-conscious consumer and drive a return to a beat/raise cycle assuming the freight environment doesn't worsen, analyst Christopher Nardone wrote in a Thursday note.There is continued strength expected in e-commerce and alternative revenue streams, and expects membership to accelerate given focus on value, improving delivery speeds, and gas saving, Nardone said.Walmart has an average rating of overweight and mean price target of $140.37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $119.53, Change: $-1.82, Percent Change: -1.50%

$WMT
Wire

Market Chatter: Mastercard Asks Brazil's Payment Processors to Help Pay for Banco Master Failure

Mastercard (MA) is looking to minimize its losses from Banco Master's failure by asking some of Brazil's largest payment processors to help foot the bill, Bloomberg reported Friday, citing people familiar with the matter and documents it viewed.Mastercard was the network for the cards issued by Banco Master's fintech, Will Financeira, which collapsed and left the payment company responsible for reimbursing merchant acquirers that processed about 5 billion reais ($997 million) of cardholder payments, the report said.Mastercard has already paid back payment processors for about half of that amount, but it's now proposing that it will use any money collected from card customers to reimburse itself before passing further funds to those merchant acquirers, the report said, citing the people and the documents.Mastercard didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $500.31, Change: $+0.69, Percent Change: +0.14%

$MA
Wire

AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer

AstraZeneca (AZN) and Daiichi Sankyo said Friday that the US Food and Drug Administration has approved Datroway for first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.The approval followed the FDA's priority review based on phase 3 data showing Datroway, or datopotamab deruxtecan, improved median overall survival to 23.7 months compared with 18.7 months for patients treated with chemotherapy, the companies said.Datroway also reduced the risk of disease progression or death by 43%, with median progression-free survival of 10.8 months versus 5.6 months for chemotherapy, according to the companies.The safety profile of Datroway was evaluated in 319 patients, with serious adverse reactions including pneumonia, vomiting, COVID-19 and anemia reported in more than 1% of patients, while one fatality was linked to interstitial lung disease or pneumonitis, Daiichi Sankyo said.Datroway is a TROP2-directed antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca.Shares of AstraZeneca were down 1.4% in Friday trading.Price: $187.16, Change: $-2.59, Percent Change: -1.36%

$AZN